Press release
Eisenmenger Syndrome Treatment Market to see Rapid Growth by 2031 | AstraZeneca, Bayer AG, Johnson & Johnson Pte. Ltd
Eisenmenger Syndrome Treatment Market
July 2021- The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US Food and Drug Administration (FDA) has approved UPTRAVI (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension in adult patients with WHO functional class (FC) II-III, who are temporarily unable to take oral therapy. UPTRAVI IV is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy, as uninterrupted treatment is considered key for individuals with PAH.
Get Free Sample link @ https://www.omrglobal.com/request-sample/eisenmenger-syndrome-treatment-market
April 2021- The US FDA has granted a second approval to treprostinil (Tyvaso) inhalation solution, for the patines. Tyvaso DPI is the only therapy approved by the FDA for PH-ILD, when the blood pressure in the lungs is high due to a disease that causes lung scarring. Moreover, the convenience and portability of Tyvaso DPI make it an important new option for patients with WHO Group 1 PAH and with WHO Group 3 PH-ILD, with the potential for improving the quality of life for this patient population.
Full report of Eisenmenger Syndrome Treatment Market available @ https://www.omrglobal.com/industry-reports/eisenmenger-syndrome-treatment-market
Market Coverage
Segment Covered- by drug type, by diagnosis, by distribution channel
Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
Competitive Landscape includes- AstraZeneca, Bayer AG, Johnson & Johnson Pte. Ltd Pharmaceuticals Corp., Pfizer Inc., GlaxoSmithKline,Hikma Pharmaceuticals PLC, and others.
Key questions addressed by the report
What is the market growth rate?
Which segment/region dominates the market in the base year?
Which segment/region will project the fastest growth in the market?
How has COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected region/segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?
Global Eisenmenger Syndrome Treatment Market- Segmentation
By Drug Type
Antiarrhythmic Agents
Blood Thinning Agents
Endothelin Receptor Antagonist
Others
By Diagnosis
Blood tests
Electrocardiogram (ECG)
Chest X-ray
Echocardiogram
Computerized tomography (CT) scan
Magnetic resonance imaging (MRI)
Cardiac catheterization
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Global Eisenmenger Syndrome Treatment Market by Region
North America
US
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of the World
Middle East & Africa
Latin America
Reasons to Buying From us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/eisenmenger-syndrome-treatment-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Eisenmenger Syndrome Treatment Market to see Rapid Growth by 2031 | AstraZeneca, Bayer AG, Johnson & Johnson Pte. Ltd here
News-ID: 3809465 • Views: …
More Releases from Orion Market Research
Hair Accessories Market Poised for Strong Growth Driven by Gen Z Trends and Sust …
Hair accessories market was valued at $23.8 billion in 2024 and is projected to reach $55.2 billion in 2035, growing at a CAGR of 8.2% during the forecast period (2025-2035). Generation Z, with significant disposable income, is transforming the hair accessories category in a major way. Their close connection to trends creates a unique feeling of urgency to self-express through fashion, such as clips, scrunchies, and barrettes. It has become…
Railway Management System Market Size Analysis, Competitive Insights, Leading Pl …
Railway System (or Railway Management System) market was valued at approximately USD 28.28 billion, and it is expected to reach about USD 45.19 billion by 2033, growing at a CAGR of around 4.8% from 2024 to 2033.
Railway Management System Market Overview
The Railway Management System market includes technologies and systems used to plan, monitor, and manage railway operations-everything from traffic and signaling systems to asset and maintenance management, passenger information,…
Monocalcium Phosphate Market Size Analysis, Competitive Insights, Leading Player …
Monocalcium Phosphate market was valued at about USD 4.2 billion, and it is anticipated to reach around USD 6.9 billion by 2033, growing at a CAGR of approximately 5% from 2023 to 2033.
Monocalcium Phosphate Market Overview
Monocalcium phosphate (MCP) is a calcium-phosphorus compound widely used in animal feed, fertilizers, and also in food and beverage applications (for example as leavening agent or acidity regulator), due to its solubility and bioavailability. The…
Automotive Lubricants Market Size Analysis, Competitive Insights, Leading Player …
Automotive Lubricants Market was valued at approximately USD 70.44 billion. By 2033, it is expected to reach around USD 107.09 billion, growing at a CAGR of about 3.3% from 2025 to 2033.
Automotive Lubricants Market Overview
The automotive lubricants market consists of products like engine oils, gear oils, greases, hydraulic fluids, and transmission fluids that reduce friction, wear and tear, and improve efficiency and lifespan of vehicle components. Demand is driven by…
More Releases for Eisenmenger
Eisenmenger Complex Market Emerging Trends and Growth Prospects 2034
Eisenmenger complex is a rare and severe complication of congenital heart disease, typically arising from untreated ventricular septal defects (VSDs), atrial septal defects (ASDs), or patent ductus arteriosus (PDA). Over time, prolonged left-to-right cardiac shunts increase pulmonary vascular resistance, eventually reversing blood flow and leading to cyanosis, right heart failure, and systemic complications.
Patients with Eisenmenger complex often face significant morbidity, including arrhythmias, hemoptysis, and thromboembolic events. Historically, treatment was limited…
Eisenmenger Syndrome Treatment Market - Industry Trends and Forecast to 2032
In 2023, the global Eisenmenger Syndrome Treatment market was valued at approximately USD 1.2 billion. It is projected to reach around USD 2.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2032.
Eisenmenger Syndrome Treatment Market Overview
The Eisenmenger Syndrome Treatment market is experiencing steady growth, primarily driven by increasing awareness of congenital heart diseases and advancements in medical technologies. Eisenmenger syndrome, a…
Eisenmenger Syndrome Treatment Market Will Exhibit an Impressive Expansion by 20 …
The global eisenmenger syndrome treatment market is anticipated to grow at a CAGR during the forecast period. The triad of systemic-to-pulmonary congenital cardiovascular communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The major factor that drives the market is consistent regulatory approval to the key players operating in the global market for the treatment of Eisenmenger syndrome by providing drugs, and therapy is expected to drive the market…
Eisenmenger Syndrome Treatment Market Will Exhibit an Impressive Expansion by 20 …
The global eisenmenger syndrome treatment market is anticipated to grow at a CAGR during the forecast period. The triad of systemic-to-pulmonary congenital cardiovascular communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The major factor that drives the market is consistent regulatory approval to the key players operating in the global market for the treatment of Eisenmenger syndrome by providing drugs, and therapy is expected to drive the market…
Eisenmenger Complex Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Eisenmenger Complex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Eisenmenger Complex, historical and forecasted epidemiology, as well as the Eisenmenger Complex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Eisenmenger Complex market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Eisenmenger Complex market size…
Eisenmenger Syndrome Treatment Market to see Rapid Growth by 2029
The global eisenmenger syndrome treatment market is anticipated to grow at a CAGR during the forecast period. The triad of systemic-to-pulmonary congenital cardiovascular communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The major factor that drives the market is consistent regulatory approval to the key players operating in the global market for the treatment of Eisenmenger syndrome by providing drugs, and therapy is expected to drive the market…
